Radioligand therapy is transforming oncology by delivering targeted radiation directly to tumors while sparing healthy tissue. Recent approvals and rapid innovation in alpha- and beta-emitting isotopes have accelerated clinical momentum, yet many programs still face challenges including heterogeneous target expression, treatment resistance, limited radiation range and suboptimal tumor microenvironments that constrain therapeutic efficacy.
This webinar explores how combination strategies can address these barriers and attendees can register to learn practical approaches for building effective regimens. Combination strategies offer a powerful path forward.
By integrating radioligand therapy with complementary modalities such as targeted therapies, chemotherapy, DNA damage repair inhibitors, external beam radiation and immunotherapy, researchers can amplify DNA damage, sensitize tumors, enhance target expression and stimulate anti-tumor immune responses. However, realizing these benefits requires careful experimental planning, biologically relevant preclinical models, quantitative imaging and dosimetry and thoughtful safety assessment to balance efficacy with toxicity.
In this webinar, the featured speaker will explore the scientific rationale and translational tools needed to design and evaluate effective radioligand therapy combinations. Attendees will gain practical insights into mechanism-based pairing strategies, model selection, imaging biomarkers, dosing considerations and emerging clinical trends that help de-risk development and accelerate programs from discovery to clinic.
Learn more about Perceptive Discovery’s Preclinical RLT services here.
Presenter:
Julian Goggi, PhD, Director, Discovery Research, Perceptive Discovery
Julian Goggi, PhD, is a Translational Scientist with over 20 years of experience in radiopharmaceutical research and development, specializing in the development of radioligand therapies and diagnostic radiopharmaceuticals across oncology, neurology and metabolic diseases. He has held senior roles in Europe and Asia, managing multidisciplinary teams and collaborations, and has authored over 60 peer-reviewed publications. He is currently serving as Director and Scientific Lead at Perceptive Inc, overseeing IND-enabling studies for radioligand therapy development.
